Study represents the first research completed on the
long-term toxicity and lifespan effects of cannabidiol in the
preclinical model C. elegans
SMITHS FALLS, ON, Nov. 23, 2020 /PRNewswire/ - Canopy Growth
Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NASDAQ:
CGC) and its medical division, Spectrum Therapeutics, have
completed and published a new study on the long-term effects of
cannabidiol (CBD), specifically focusing on toxicity and lifespan
effects of CBD in the preclinical model C. elegans.
The study was commissioned to evaluate the solubility,
stability, acute toxicity, thermotolerance, and effects on lifespan
of CBD in C. elegans as part of Canopy Growth's ongoing
commitment to provide the data required to support and influence
public policy through research. To the best of the Company's
knowledge, this study represents the first long-term toxicity and
lifespan research regarding the effects of chronic exposure to
cannabidiol – one of the cannabinoids found in cannabis.
Acute and long-term exposure studies of CBD at physiologically
relevant concentrations were studied in the worm model
Caenorhabditis elegans (C. elegans) on the basis that
60-80% of their genes are shared with humans, and their
comparatively short lifespan of 2-3 weeks makes such studies
feasible. In the C. elegans model, which is recognized as a
valid model for this kind of research, CBD did not demonstrate any
degree of acute or life-long toxicity or related liabilities at
physiological concentrations. Instead, CBD extended mean lifespan
up to 18% and increased late-stage life activity by up to 206%
compared to the untreated controls within the study.
"Despite widespread use of CBD, no life-long toxicity studies
had been conducted to date to determine the impact – or potential
impact – of long-term exposure to CBD," shared Hunter Land, Senior Director of Translational
and Discovery Science at Canopy Growth. "These results serve as the
only CBD life-long exposure data in an in vivo model to
date, and the absence of long-term toxicity gives us the evidence
we need as an industry to continue researching the potential health
benefits for the broader application of CBD."
The study was conducted in partnership with NemaLife Inc., and
is published in Cannabis and Cannabinoid Research journal and
available online.
While further research into the life-long use of CBD should be
carried out in mammalian models, the C. elegans model
indicates a lack of long-term toxicity at physiologically relevant
concentrations. Canopy Growth and its medical division Spectrum
Therapeutics continue to advance a range of research initiatives
aimed at furthering the understanding of – and unleashing – the
full potential of cannabis.
About Canopy Growth Corporation
Canopy Growth (TSX:WEED,NASDAQ:CGC) is a world-leading
diversified cannabis and cannabinoid-based consumer product
company, driven by a passion to improve lives, end prohibition, and
strengthen communities by unleashing the full potential of
cannabis. Leveraging consumer insights and innovation, we
offer product varieties in high quality dried flower, oil, softgel
capsule, infused beverage, edible, and topical formats, as well as
vaporizer devices by Canopy Growth and industry-leader Storz &
Bickel. Our global medical brand, Spectrum Therapeutics, sells a
range of full-spectrum products using its colour-coded
classification system and is a market leader in both Canada and Germany. Through our award-winning Tweed and
Tokyo Smoke banners, we reach our adult-use consumers and have
built a loyal following by focusing on top quality products and
meaningful customer relationships. Canopy Growth has entered into
the health and wellness consumer space in key markets including
Canada, the United States, and Europe through BioSteel sports nutrition, and
This Works skin and sleep solutions; and has introduced additional
federally-permissible CBD products to the
United States through our First & Free and Martha
Stewart CBD brands. Canopy Growth has an established partnership
with Fortune 500 alcohol leader Constellation Brands. For more
information visit www.canopygrowth.com.
Notice Regarding Forward Looking Statements
This press release contains "forward-looking statements" and
"forward-looking information" within the meaning of applicable U.S.
and Canadian securities laws (collectively, "forward-looking
statements"), which involve certain known and unknown risks and
uncertainties. Forward-looking statements predict or describe our
future operations, business plans, business and investment
strategies and the performance of our investments. These
forward-looking statements are generally identified by their use of
such terms and phrases as "intend," "goal," "strategy," "estimate,"
"expect," "project," "projections," "forecasts," "plans," "seeks,"
"anticipates," "potential," "proposed," "will," "should," "could,"
"would," "may," "likely," "designed to," "foreseeable future,"
"believe," "scheduled" and other similar expressions. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date the statement was made.
Forward–looking statements are necessarily based upon a number of
estimates and assumptions that, while considered reasonable by
management, are inherently subject to significant business,
economic and competitive risks, financial results, results,
performance or achievements expressed or implied by those
forward–looking statements and the forward–looking statements are
not guarantees of future performance. Accordingly, there are or
will be important factors that could cause actual outcomes or
results to differ materially from those indicated in these
statements. A discussion of some of the material factors applicable
to Canopy Growth Corporation ("Canopy") can be found under the
section entitled "Risk Factors" in Canopy's Annual Report on Form
10-K for the year ended March 31,
2020, filed with the Securities and Exchange Commission and
with applicable Canadian securities regulators, as such factors may
be further updated from time to time in its periodic filings with
the Securities and Exchange Commission and with applicable Canadian
securities regulators, which can be accessed at
www.sec.gov/edgar and www.sedar.com, respectively. These
factors should not be construed as exhaustive and should be read in
conjunction with the other cautionary statements that are included
in this press release and in the filings. Any forward–looking
statement included in this press release is made as of the date of
this press release and, except as required by law, Canopy disclaims
any obligation to update or revise any forward– looking statement.
Readers are cautioned not to put undue reliance on any
forward–looking statement. Forward-looking statements contained in
this press release are expressly qualified by this cautionary
statement.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/canopy-growth-announces-completion-of-study-on-the-long-term-effects-of-cbd-301178311.html
SOURCE Canopy Growth Corporation